{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:18:59Z","timestamp":1785799139097,"version":"3.56.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enfortumab vedotin (EV), a Nectin-4\u2013directed antibody\u2013drug conjugate, improves survival in patients with locally advanced or metastatic urothelial carcinoma (la\/mUC) after prior platinum-based chemotherapy and immune checkpoint inhibitors. However, EV-associated cutaneous adverse events (AEs) may be underrecognized in real-world practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a pharmacovigilance study using the U.S. FDA Adverse Event Reporting System (FAERS) database (2020\u20132025). EV-related cutaneous AE reports were identified and descriptively characterized. Disproportionality analyses were conducted to detect safety signals, and time-to-onset (TTO) was evaluated. Multivariable analyses were used to explore clinical factors associated with cutaneous AEs and death among EV reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,389 EV-associated cutaneous AE cases were identified. The most frequently reported events were rash, pruritus, and alopecia, alongside severe reactions including Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. We detected 44 positive cutaneous safety signals, including 10 not described in the EV label. Most cutaneous AEs occurred early after treatment initiation and were reported predominantly in elderly male patients. Concomitant prednisolone use was associated with higher reporting of cutaneous AEs and increased mortality, whereas concomitant amlodipine use was associated with lower reporting of cutaneous AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Real-world FAERS data indicate that enfortumab vedotin is associated with a broad and evolving spectrum of cutaneous adverse events, including early-onset and potentially life-threatening reactions. We identified 10 previously unlabeled safety signals, and most events occurred within the first 2 weeks after treatment initiation. The proposed clinical priority framework may help support risk stratification and pharmacovigilance monitoring. Although causality cannot be established using spontaneous reporting data, these findings highlight the importance of early dermatologic surveillance and individualized safety management during EV therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1792256","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:12:11Z","timestamp":1775707931000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"13","author":[{"given":"Pan","family":"Ding","sequence":"first","affiliation":[{"name":"Department of Urology, Nanchang People's Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanchang People's Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leihua","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Urology, Nanchang People's Hospital","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur Urol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)-A summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eururo.2025.02.010","article-title":"A systematic review of novel intravesical approaches for the treatment of patients with non-muscle-invasive bladder cancer","volume":"88","author":"Ghodoussipour","year":"2025","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ."},{"key":"B7","doi-asserted-by":"publisher","first-page":"17562872241249073","DOI":"10.1177\/17562872241249073","article-title":"Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer","volume":"16","author":"Domb","year":"2024","journal-title":"Ther Adv Urol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.urolonc.2023.03.012","article-title":"Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced\/metastatic urothelial carcinoma by cisplatin-eligibility","volume":"41","author":"Morgans","year":"2023","journal-title":"Urol Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.3390\/ijms21197268","article-title":"Targeted molecular therapeutics for bladder cancer-a new option beyond the mixed fortunes of immune checkpoint inhibitors?","volume":"21","author":"Bednova","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA approval summary: enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.eururo.2024.01.007","article-title":"Health-related quality of life in patients with previously treated advanced urothelial carcinoma from EV-301: a phase 3 trial of enfortumab vedotin versus chemotherapy","volume":"85","author":"Rosenberg","year":"2024","journal-title":"Eur Urol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1177\/13524585211055934","article-title":"Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: phase 2 APOLITOS study","volume":"28","author":"Kira","year":"2022","journal-title":"Mult Scler."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1111\/ddg.14617","article-title":"A distinctive bullous skin reaction associated with enfortumab vedotin-ejfv treatment for metastatic urothelial cancer: a case report","volume":"19","author":"Krause","year":"2021","journal-title":"J Dtsch Dermatol Ges."},{"key":"B19","doi-asserted-by":"publisher","first-page":"621591","DOI":"10.3389\/fonc.2021.621591","article-title":"Case report: enfortumab vedotin for metastatic urothelial carcinoma: a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal stevens-johnson syndrome\/toxic epidermal necrolysis to dermal hypersensitivity reaction","volume":"11","author":"Viscuse","year":"2021","journal-title":"Front Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/14796694.2025.2482363","article-title":"Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer","volume":"21","author":"Sternschuss","year":"2025","journal-title":"Future Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"801199","DOI":"10.3389\/fonc.2021.801199","article-title":"Cutaneous toxicity associated with enfortumab vedotin: a real-word study leveraging US Food and Drug Administration Adverse event reporting system","volume":"11","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13195-025-01728-4","article-title":"Reply: [post-marketing safety concerns with Lecanemab: a disproportionality analysis using the FDA adverse event reporting system]","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimers Res Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/pds.5624","article-title":"Sensitivity and specificity in signal detection with the reporting odds ratio and the information component","volume":"32","author":"Trillenberg","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1377842","DOI":"10.3389\/fonc.2024.1377842","article-title":"Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience","volume":"14","author":"Vlachou","year":"2024","journal-title":"Front Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.esmorw.2024.100094","article-title":"Incidence, risk factors, and clinical implications of enfortumab vedotin-related cutaneous toxicity in urothelial carcinoma: a large-scale, real-world study in Japan","volume":"7","author":"Kita","year":"2025","journal-title":"ESMO Real World Data and Digital Oncology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1354543","DOI":"10.3389\/fonc.2024.1354543","article-title":"Therapeutic prospects of nectin-4 in cancer: applications and value","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jdcr.2021.07.010","article-title":"Toxic epidermal necrolysis-like toxic erythema of chemotherapy: 2 illustrative cases","volume":"15","author":"Lu","year":"2021","journal-title":"JAAD Case Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/DAD.0000000000002255","article-title":"Enfortumab vedotin-associated toxic epidermal necrolysis-like toxic erythema of chemotherapy","volume":"44","author":"Birmingham","year":"2022","journal-title":"Am J Dermatopathol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s40264-019-00825-2","article-title":"Mechanisms of severe cutaneous adverse reactions: recent advances","volume":"42","author":"Bell\u00f3n","year":"2019","journal-title":"Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jaci.2012.08.042","article-title":"Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"131","author":"Teraki","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1089\/wound.2019.0977","article-title":"Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensive review","volume":"9","author":"Charlton","year":"2020","journal-title":"Adv Wound Care."},{"key":"B37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2165\/00002018-199513010-00007","article-title":"Drug-induced severe skin reactions. Incidence, management and prevention","volume":"13","author":"Wolkenstein","year":"1995","journal-title":"Drug Saf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"702264","DOI":"10.3389\/fphar.2021.702264","article-title":"Calcium channels: noteworthy regulators and therapeutic targets in dermatological diseases","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/17512433.2021.1894128","article-title":"Use of calcium channel blockers in dermatology: a narrative review","volume":"14","author":"Lo","year":"2021","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41586-024-07282-7","article-title":"Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids","volume":"629","author":"Auger","year":"2024","journal-title":"Nature."},{"key":"B41","doi-asserted-by":"publisher","first-page":"106869","DOI":"10.1016\/j.aquatox.2024.106869","article-title":"Prednisone and prednisolone effects on development, blood, biochemical and histopathological markers of Aquarana catesbeianus tadpoles","volume":"268","author":"Rutkoski","year":"2024","journal-title":"Aquat Toxicol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/iju5.70036","article-title":"Enfortumab vedotin-induced toxic epidermal necrolysis in metastatic urothelial carcinoma complicated by severe gastrointestinal bleeding","volume":"8","author":"Matsuyama","year":"2025","journal-title":"IJU Case Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e40597","DOI":"10.7759\/cureus.40597","article-title":"Ocular toxicity profile of targeted cancer therapy (TCT) at a US tertiary cancer center","volume":"15","author":"Ameri","year":"2023","journal-title":"Cureus."},{"key":"B44","doi-asserted-by":"publisher","first-page":"115427","DOI":"10.1016\/j.ejca.2025.115427","article-title":"Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin","volume":"222","author":"Belka\u00efd","year":"2025","journal-title":"Eur J Cancer."},{"key":"B45","doi-asserted-by":"publisher","first-page":"17588359221108690","DOI":"10.1177\/17588359221108690","article-title":"Gender dimorphism in survival of patients with lymph node metastasis of bladder cancer","volume":"14","author":"Guo","year":"2022","journal-title":"Ther Adv Med Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.eururo.2024.03.011","article-title":"Re: EV-301 long-term outcomes: 24-month findings from the phase iii trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"86","author":"Drake","year":"2024","journal-title":"Eur Urol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/1060028020960402","article-title":"Enfortumab Vedotin-ejfv: a first-in-class anti-nectin-4 antibody-drug conjugate for the management of urothelial carcinoma","volume":"55","author":"Halford","year":"2021","journal-title":"Ann Pharmacother."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1792256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:12:13Z","timestamp":1775707933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1792256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":47,"alternative-id":["10.3389\/fmed.2026.1792256"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1792256","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"article-number":"1792256"}}